International Psychogeriatrics

Clinical use of neuroimaging in dementia: an international perspective

CONTENTS

Guest Editorial S1 Clinical use of neuroimaging in dementia: an international perspective
John O'Brien (UK) and Philip Scheltens (The Netherlands)

Reviews S6 The use of CT in dementia
Marco Parietti, Anna Poggesi and Giovanna Filippini (Italy)

S13 Structural MRI
Marco Parietti (The Netherlands)

S25 Perfusion SPECT and FDG-PET
Erik Verbaan (The Netherlands)

S32 Dopaminergic imaging: clinical utility now and in the future
Jonathan Schott and Janine Feilds (UK)

S41 Amyloid imaging
Zuzana Walker and Joanne Rodda (UK)

S50 Other magnetic resonance imaging techniques
Klaus P. Ebmeier, Nicola Filippini, Verena Heise and Claire E. Sexton (UK)

S58 An international perspective on advanced neuroimaging: cometh the hour or ivory tower?
Craig W. Ritchie (UK), David Ames (Australia), James R. Burke (U.S.A.), Julian Bustin (Argentina), Peter Connelly (UK), Jan Laczo (Czech Republic) and Florence Portet (France)
Clinical use of neuroimaging in dementia: an international perspective

Edited by
John O’Brien and Philip Scheltens

Disclaimer

This supplement was supported by an unrestricted educational grant from GE Healthcare. The content was independently developed, commissioned and reviewed by the supplement editors.

The editors declare the following interests:

Professor O’Brien is Deputy Editor of International Psychogeriatrics and serves as an editorial board member for Psychological Medicine. He has been a consultant for GE Healthcare, Servier and Bayer Healthcare and has received honoraria for non-promotional talks from Pfizer, GE Healthcare, Eisai, Shire, Lundbeck, Lilly, Wyeth and Novartis.

Professor Scheltens serves/has served on the advisory boards of Genentech, Novartis, Roche, Danone, Nutricia, Baxter, GE Healthcare and Lundbeck. He has been a speaker at symposia organised by Lundbeck, Merz, Danone, Novartis, Roche and Genentech. For all such activities he receives no personal compensation. He currently serves on the editorial board of Alzheimer’s Research and Therapy and Alzheimers Disease and Associated Disorders, and is a member of the scientific advisory board of the EU Joint Programming Initiative and the French National Plan Alzheimer. The Alzheimer Center in Amsterdam receives unrestricted funding from various sources through VUMC fonds.